The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
In September, Vertex filed for Chapter 11 bankruptcy protection and accused Irving, Texas-based Matheson Tri-Gas Inc. of ...
Hosted on MSN1d
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should KnowVertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...
11don MSN
Different genetic mutations cause different problems with this particular protein -- so CFTR modulators generally don't work ...
Vertex (VERX) has received a new Buy rating, initiated by D.A. Davidson analyst, Will Jellison.Don't Miss Our New Year's Offers:Discover the ...
Vertex stock plummeted Thursday after the company's pain drug proved it's no better than a placebo in patients with lower ...
Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $57.33, along ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback